Institutional Trading Insights
Institutional Investors Show Mixed Trading Across Tech, Industrials, and Healthcare Sectors
Anonymous
Key Points
1
For Celestica (CLS), Clark’s 51% trim to 221,918 shares came alongside a higher analyst consensus with specific upside targets: BMO Capital Markets raised its price target from $370 to $450 and reiterated an “outperform,” while TD Cowen upgraded from “hold” to “buy” and lifted its target from $350 to $430 (plus other upgrades noted). Institutional ownership/hedge-fund ownership was cited at 67.38%.
2
For Qualcomm (QCOM), the filings included not just &PARTNERS’s 13.2% increase, but also a CEO transaction: “CEO Cristiano R. Amon sold 10,000 shares of Qualcomm stock” (in addition to multiple other institutional investors increasing stakes). The article also reports institutional/hedge-fund ownership at 74.35%.
3
For Trane Technologies (TT), Munro Partners’ 6.5% reduction was accompanied by disclosed insider selling: CFO Christopher J. Kuehn sold 8,619 shares at an average price of $450.00 for $3,878,550 and the trade was executed under a pre-arranged Rule 10b5-1 trading plan. The article also states institutional/hedge-fund ownership at 82.97%.
4
For Liberty Media – Liberty Formula One Series C (FWONK), the article adds portfolio context and other heavyweight buying: it says Munro Partners’ FWONK stake is ~3.6% of its investment portfolio and the 8th-largest position, while Norges Bank purchased a new stake valued at about $195.762 million. Hedge funds and other institutions were reported at 92.26% ownership.
5
For Insulet (PODD), beyond Munro Partners cutting its position by 88.4%, the article provides market and balance-sheet snapshot data: PODD opened at $148.14; it cited a 52-week low of $140.63 and 52-week high of $354.88; and it reported a debt-to-equity ratio of 0.71 (with a quick ratio also mentioned).
Clark Capital Management Group slashed its Celestica (CLS) stake by 51%, trimming to 221,918 shares worth about $65.6 million, even as Wall Street analysts piled on upgrades for the AI data-center supplier. The move is part of a broader wave of institutional rebalancing revealed in recent SEC filings, spanning tech, industrials, healthcare, and media.
The filings show no single directional bet. Some funds cut big winners while others added to positions — and insider selling at several companies added another layer of complexity for retail investors watching these moves.
Analysts Bullish on Celestica Even as Clark Capital Exits
Clark Capital cut its Celestica position in half despite a chorus of analyst upgrades. BMO Capital Markets raised its price target from $370 to $450 and kept an "outperform" rating. TD Cowen went further, upgrading from "hold" to "buy" and lifting its target from $350 to $430. Both pointed to sustained spending by hyperscalers — the big cloud companies like Google, Amazon, and Microsoft — on AI data-center hardware.
Celestica reported Q1 2026 revenue of $4.05 billion, up 53% from a year earlier, and raised its annual outlook to roughly $19 billion. Yet Clark Capital, which is being acquired by Raymond James Investment Management, still chose to lock in gains. Institutional ownership sits at 67.38%, leaving room for further selling pressure if more funds follow suit.
Qualcomm Gains Institutional Buyers but Loses Its CEO's Shares
&PARTNERS raised its Qualcomm (QCOM) stake by 13.2% to 280,598 shares, worth roughly $48 million. Several other institutional investors also added to positions, keeping overall institutional ownership near 74.35%. Qualcomm posted $10.60 billion in revenue in its most recent quarter, and analysts at firms like InvestingPro view the stock as fairly valued near $192.
At the same time, CEO Cristiano R. Amon sold 10,000 shares at an average price of $185.00 in early May under a pre-arranged Rule 10b5-1 plan — a type of scheduled selling program that executives use to avoid insider-trading concerns. The sale netted roughly $1.85 million and came just days after Qualcomm's earnings release.
Munro Partners Bets Big on Formula One, Dumps Insulet
Australian fund Munro Partners made the sharpest moves in the batch. It raised its Liberty Media Formula One Series C (FWONK) stake by 4.7% to 1,418,568 shares worth about $139.7 million — its 8th-largest position at 3.6% of its portfolio. Norway's sovereign wealth fund, Norges Bank, also made a new bet on the same stock, buying roughly 1,987,228 shares valued at about $195.8 million. Institutional and hedge-fund ownership in FWONK now stands at 92.26%.
Munro also slashed its Insulet (PODD) position by 88.4%, dropping from roughly 227,000 shares to just 26,470 shares worth about $7.5 million. Insulet, which makes the Omnipod insulin pump, opened recently at $148.14 — far below its 52-week high of $354.88. Broader concerns about GLP-1 weight-loss drugs reducing demand for insulin devices appear to be weighing on investor confidence in the sector. The stock's debt-to-equity ratio stands at 0.71.
Trane Technologies CFO Locks In $3.9 Million at $450 a Share
Munro Partners also trimmed its Trane Technologies (TT) stake by 6.5% to 16,895 shares worth about $6.6 million. More eye-catching was the insider move: CFO Christopher J. Kuehn sold 8,619 shares at exactly $450.00 each, collecting $3,878,550. The sale was made under a pre-arranged Rule 10b5-1 plan, meaning it was scheduled in advance and not a reaction to breaking news.
Trane has been a beneficiary of global climate-focused spending, and its institutional ownership is a hefty 82.97%. The CFO's decision to sell near $450 may signal that insiders see that level as a near-term ceiling — something retail investors should watch if the stock approaches that price again in Q3.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
11
Reach
32
A
AnonymousAuthor
